The internationally renowned expert in the calculation and communication of risk and statistics, Sir David Spiegelhalter, discusses the concept of a ‘preference zone’ to frame the demands of safety, efficacy and choice in the era of personalised medicine.
Similar Posts
Breast implant associated anaplastic large cell lymphoma (BIA-ALCL)
Information for patients, public and healthcare professionals.
MHRA Safety Roundup: October 2025
Summary of the latest safety advice for medicines and medical device users
Decision: Advertising Investigations: October 2025
Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
Guidance: Borderline products: medical devices and other products
How the MHRA makes decisions on whether a borderline product is a medical device and whether medical devices regulations should apply.
Guidance: Medical devices: periodic safety update report
Information and recommendations for approved bodies on the presentation and review of a periodic safety update report (PSUR).
Class 2 Medicines Recall: Depo-Medrone 80 mg in 2 mL, Maxearn Limited EL(25)A/29
A batch of Depo-Medrone has been released to the market with an error. The vial over label incorrectly states that the total vial content is 40 mg in 1 mL, when the correct total vial content is 80mg in 2 mL (with a concentration of 40mg/ml of methylprednisolone acetate).